101140 — InBioGen Co Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.89% | ||
| Return on Equity | 15.31% | ||
| Operating Margin | -1264.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 9,795.2 | 10,217.71 | 10,480.82 | 10,419.52 | 6,240.8 | n/a | n/a | -3.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InBioGen Co Ltd, formerly BTOne Co Ltd, is a company mainly engaged in the operation of the kiosk business. The Company operates its business through four segments. The Kiosk Business segment is engaged in the operation of unmanned payment machine business in restaurants, karaoke rooms, and personal computer (PC) rooms. The Footwear Business segment is mainly engaged in the sale of children's shoes and adult shoes. The Wood Pellet Business segment mainly sells wood pellets and sawdust. The Other Business segment engages in online and offline education business to foster human resources in the FinTech service, platform business, and block chain industry.
Directors
- Sang Jun Lee CEO
- Tae Jeong Ha VPR (50)
- Jong Hwan Kim VPR (55)
- Seong Yeop Jung VPR
- Yeong Hun Gwon OTH (67)
- Seong Man Hwang OTH (53)
- Byeong Ho Lee DRC (54)
- Yeong Seo Park DRC (54)
- Jin Bang Kim NID
- Yeong Gyun Kim NID (38)
- Seong Wu Nam NID (50)
- Gil Je Ryu NID (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 5th, 2008
- Public Since
- April 2nd, 2008
- No. of Shareholders
- 19,446
- No. of Employees
- 64
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 9,984,772
- Address
- 11, Hakdong-ro 25-gil, Gangnam-gu, SEOUL, 06095
- Web
- http://www.inbiogen.co.kr/
- Phone
- +82 269787183
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 101140
Similar to 101140
AJ Networks Co
Korea Exchange - KSE
Daekyo Co
Korea Exchange - KSE
Daesung Holdings Co
Korea Exchange - KSE
Fursys
Korea Exchange - KSE
Hanchang
Korea Exchange - KSE
FAQ
As of Today at 19:11 UTC, shares in InBioGen Co are trading at KR₩9,340. This share price information is delayed by 15 minutes.
Shares in InBioGen Co last closed at KR₩9,340 and the price had moved by +208.25% over the past 365 days. In terms of relative price strength the InBioGen Co share price has outperformed the FTSE Developed Asia Pacific Index by +210.38% over the past year.
There is no consensus recommendation for this security.
InBioGen Co does not currently pay a dividend.
InBioGen Co does not currently pay a dividend.
InBioGen Co does not currently pay a dividend.
To buy shares in InBioGen Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩9,340, shares in InBioGen Co had a market capitalisation of .
Here are the trading details for InBioGen Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 101140
Based on an overall assessment of its quality, value and momentum InBioGen Co is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InBioGen Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +574.85%.
As of the last closing price of KR₩9,340, shares in InBioGen Co were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The InBioGen Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩9,340.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
InBioGen Co's management team is headed by:
- Sang Jun Lee - CEO
- Tae Jeong Ha - VPR
- Jong Hwan Kim - VPR
- Seong Yeop Jung - VPR
- Yeong Hun Gwon - OTH
- Seong Man Hwang - OTH
- Byeong Ho Lee - DRC
- Yeong Seo Park - DRC
- Jin Bang Kim - NID
- Yeong Gyun Kim - NID
- Seong Wu Nam - NID
- Gil Je Ryu - NID